NAYA Biosciences, Inc Cash Flow Conversion Efficiency
NAYA Biosciences, Inc cash flow conversion efficiency. Based on the latest financial reports, NAYA Biosciences, Inc (NAYA) has a cash flow conversion efficiency ratio of -0.048x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-617.38K) by net assets ($12.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of NAYA Biosciences, Inc (2007–2024)
Cash flow conversion efficiency of NAYA Biosciences, Inc from 2007 to 2024. This chart illustrates how NAYA Biosciences, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for NAYA Biosciences, Inc for real-time trading data and today's change.
NAYA Biosciences, Inc Cash Flow Conversion Ratio Explained
NAYA Biosciences, Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
NAYA Biosciences, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NAYA Biosciences, Inc ranked by their cash flow conversion efficiency. Also see NAYA Biosciences, Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gulf Marine Services PLC
LSE:GMS
|
0.101x |
|
Lexus Granito (India) Limited
NSE:LEXUS
|
0.285x |
|
Fjordland Exploration Inc
V:FEX
|
2.832x |
|
Richmond Minerals Inc
V:RMD
|
-0.020x |
|
China Pharma Holdings Inc
NYSE MKT:CPHI
|
-0.028x |
|
Halo Technologies Holdings Ltd
AU:HAL
|
0.345x |
|
PolyPlank publ AB
ST:POLY
|
0.323x |
|
Lavide Holding NV
AS:LVIDE
|
-0.350x |
Annual Cash Flow Conversion Efficiency for NAYA Biosciences, Inc (2007–2024)
The table below shows the annual cash flow conversion efficiency of NAYA Biosciences, Inc from 2007 to 2024. Review NAYA FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $12.75 Million | $-2.97 Million | -0.233x | +95.62% |
| 2023-12-31 | $892.60K | $-4.76 Million | -5.327x | -178.87% |
| 2022-12-31 | $-977.61K | $-6.60 Million | 6.755x | +918.92% |
| 2021-12-31 | $7.31 Million | $-6.03 Million | -0.825x | +0.80% |
| 2020-12-31 | $5.74 Million | $-4.78 Million | -0.831x | -125.29% |
| 2019-12-31 | $-3.71 Million | $1.37 Million | -0.369x | -253.97% |
| 2018-12-31 | $-2.72 Million | $-652.97K | 0.240x | +560.10% |
| 2017-12-31 | $-4.99 Million | $-181.27K | 0.036x | -48.23% |
| 2016-12-31 | $-4.62 Million | $-323.90K | 0.070x | +73.81% |
| 2015-12-31 | $-3.76 Million | $-151.62K | 0.040x | -68.30% |
| 2010-12-31 | $-2.48 Million | $-315.99K | 0.127x | -57.65% |
| 2009-12-31 | $-3.08 Million | $-926.66K | 0.301x | -93.61% |
| 2008-12-31 | $-226.57K | $-1.07 Million | 4.708x | +309.46% |
| 2007-12-31 | $-100.93K | $-116.04K | 1.150x | -- |
About NAYA Biosciences, Inc
INVO Fertility, Inc., a life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases. The company operates in two divisions, NAYA Women's Health and NAYA Therapeutics. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma, as well as soli… Read more